Registration Dossier
Registration Dossier
Data platform availability banner - registered substances factsheets
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 267-184-4 | CAS number: 67801-64-3
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data
Genetic toxicity: in vitro
Administrative data
- Endpoint:
- in vitro cytogenicity / micronucleus study
- Remarks:
- Type of genotoxicity: chromosome aberration
- Type of information:
- experimental study
- Adequacy of study:
- key study
- Study period:
- 22 January - 13 March 2016
- Reliability:
- 1 (reliable without restriction)
- Rationale for reliability incl. deficiencies:
- guideline study
- Remarks:
- Well conducted and well described study in accordance with GLP and OECD Guideline 487 without any deviation.
Data source
Reference
- Reference Type:
- study report
- Title:
- Unnamed
- Year:
- 2 016
Materials and methods
Test guideline
- Qualifier:
- according to guideline
- Guideline:
- other: OECD Guideline 487 (In Vitro Mammalian Cell Micronucleus Test)
- Deviations:
- no
- Principles of method if other than guideline:
- Not applicable
- GLP compliance:
- yes (incl. QA statement)
- Remarks:
- UK GLP compliance programme (inspected on 17 June 2015/ signed on 24 September 2015)
- Type of assay:
- in vitro mammalian cell micronucleus test
Test material
- Reference substance name:
- 2-tert-butylcyclohexyl ethyl carbonate
- EC Number:
- 267-184-4
- EC Name:
- 2-tert-butylcyclohexyl ethyl carbonate
- Cas Number:
- 67801-64-3
- Molecular formula:
- C13H24O3
- IUPAC Name:
- 2-tert-butylcyclohexyl ethyl carbonate
- Test material form:
- liquid
- Details on test material:
- - Physical state: Colorless liquid
- Expiration date of the lot/batch: 02 July 2016
- Storage condition of test material: At room temperature protected from light
Constituent 1
Method
- Target gene:
- None
Species / strain
- Species / strain / cell type:
- lymphocytes: human
- Details on mammalian cell type (if applicable):
- Not applicable
- Additional strain / cell type characteristics:
- not applicable
- Metabolic activation:
- with and without
- Metabolic activation system:
- 2 % S9 (final concentration); S9 fraction prepared from liver homogenates of rats induced with Phenobarbital/β-naphthoflavone.
- Test concentrations with justification for top dose:
- Preliminary Toxicity Test: 0, 8.91, 17.81, 35.63, 71.25, 142.5, 285, 570, 1140 and 2280 µg/mL (4-hour exposure to the test item without S9-mix or with S9-mix (2%); 24-hour continuous exposure to the test item without S9-mix)
Main Experiment:
4-hour exposure to the test item without S9-mix: 0, 4, 8, 16, 24, 28, 32 and 64 µg/mL.
4-hour exposure to the test item with S9-mix (2%): 0, 8, 16, 32, 56, 64, 80 and 96 µg/mL.
24-hour continuous exposure to the test item without S9-mix: 0, 8, 16, 24, 32, 40, 56 and 64 µg/mL. - Vehicle / solvent:
- - Vehicle(s)/solvent(s) used: DMSO
- The test item was soluble in DMSO at 228 mg/mL in a solubility check performed in house.
- Prior to each experiment, the test item was accurately weighed, dissolved in DMSO and serial dilutions prepared. The test item was formulated within two hours of it being applied to the test system; it is assumed that the test item formulation was stable for this duration.
Controlsopen allclose all
- Untreated negative controls:
- no
- Negative solvent / vehicle controls:
- yes
- Remarks:
- DMSO
- True negative controls:
- no
- Positive controls:
- yes
- Positive control substance:
- mitomycin C
- other: Demecolcine
- Remarks:
- Without S9 mix - Mitomycin C: 0.2 µg/mL for 4-hour exposure; Demecolcine: 0.075 µg/mL for 24-hour continuous exposure
- Untreated negative controls:
- no
- Negative solvent / vehicle controls:
- yes
- Remarks:
- DMSO
- True negative controls:
- no
- Positive controls:
- yes
- Positive control substance:
- cyclophosphamide
- Remarks:
- With S9 mix - 5 µg/mL for 4-hour exposure
- Details on test system and experimental conditions:
- TEST SYSTEM: For each experiment, sufficient whole blood was drawn from the peripheral circulation of a non smoking volunteer (18-35) who had been previously screened for suitability. The volunteer had not knowingly been exposed to high levels of radiation or hazardous chemicals and had not knowingly recently suffered from a viral infection. Based on over 20 years of in house data for cell cycle times for human lymphocytes, using BrdU (bromodeoxyuridine) incorporation to assess the number of first, second and third division metaphase cells to calculate the average generation time (AGT), it is considered to be approximately 16 hours. Therefore using this average value of the AGT the in-house experimental exposure time was 1.5 x AGT, which is 24 hours.
The details of the donors used are: Preliminary Toxicity Test: Female, aged 34 years; Main Experiment: Male, aged 28 years
CELL CULTURE: Cells (whole blood cultures) were grown in Eagle's minimal essential medium with HEPES buffer (MEM), supplemented “in-house” with L-glutamine, penicillin/streptomycin, amphotericin B and 10% fetal bovine serum (FBS), at approximately 37 ºC with 5% CO2 in humidified air. The lymphocytes of fresh heparinized whole blood were stimulated to divide by the addition of phytohaemagglutinin (PHA).
DURATION
- Exposure duration: 4 h (± S9) and 24 h continuous exposure (-S9) in preliminary toxicity test; 4 h (± S9) and 24 h continuous exposure (-S9) in main experiment
- At the end of the exposure period, the cell cultures were washed and then incubated for a further 24 h in the presence of Cytochalasin B.
SPINDLE INHIBITOR (cytogenetic assays): Prior to the mitosis (after exposure of the test substance) the chemical cytochalasin B (4.5 μg/mL) was added to the cultures.
STAIN (for cytogenetic assays): 5 % Giemsa for 5 minutes
NUMBER OF REPLICATIONS:
- Preliminary toxicity test: Single culture for test item and vehicle control
- Main test: Duplicate cultures per dose for test item, vehicle and positive controls
NUMBER OF CELLS EVALUATED:
- Cytotoxicity: A minimum of approximately 500 cells per culture were scored for the incidence of mononucleate, binucleate and multinucleate cells and the CBPI value expressed as a percentage of the vehicle controls. The CBPI indicates the number of cell cycles per cell during the period of exposure to Cytochalasin B.
- Scoring of Micronuclei: The micronucleus frequency in 2000 binucleated cells was analyzed per concentration (1000 binucleated cells per culture, two cultures per concentration). Cells with 1, 2 or more micronuclei were recorded as such but the primary analysis was on the combined data. Experiments with human lymphocytes have established a range of micronucleus frequencies acceptable for control cultures in normal volunteer donors.
DETERMINATION OF CYTOTOXICITY
- Method: Cytotoxicity of test item in the lymphocyte cultures was determined using the cytokinesis-block proliferation index (CBPI index).
% Cytostasis = 100-100{(CBPIT – 1)/(CBPIC –1)}
CBPI = [(No. mononucleate cells) + (2 x No. binucleate cells) + (3 x No. multinucleate cells)] / [Total number of cells]
T = test substance treatment culture
C = vehicle control culture
OTHER:
The criteria for identifying micronuclei were that they were round or oval in shape, non refractile, not linked to the main nuclei and with a diameter that was approximately less than a third of the mean diameter of the main nuclei. Binucleate cells were selected for scoring if they had two nuclei of similar size with intact nuclear membranes situated in the same cytoplasmic boundary. The two nuclei could be attached by a fine nucleoplasmic bridge which was approximately no greater than one quarter of the nuclear diameter. - Evaluation criteria:
- Providing that all of the acceptability criteria are fulfilled, a test item is considered to be clearly negative if, in most/all of the experimental conditions examined:
- None of the test concentrations exhibited a statistically significant increase in micronucleus frequency compared with the concurrent negative control.
- There was no dose-related increase in micronucleus frequency.
- The micronucleus frequency results in all evaluated dose groups were within the range of the laboratory historical control data.
Providing that all of the acceptability criteria are fulfilled, a test item may be considered to be clearly positive, if in any of the experimental conditions examined, there is one or more of the following applicable:
- At least one of the test concentrations exhibited a statistically significant increase in micronucleus frequency compared with the concurrent negative control.
- There was an increase in micronucleus frequency that can be considered to be dose-related.
- The micronucleus frequency results were substantially outside the range of the laboratory historical negative control data.
When all the criteria are met, the test item is considered able to induce chromosome breaks and/or gain or loss of a whole chromosome in this test system.
There is no requirement for verification of a clear positive or negative response.
In case the response is neither clearly negative nor clearly positive as described above or in order to assist in establishing the biological relevance of a result, the data should be evaluated by expert judgement and/or further investigations. The Study Director may make a judgement based on experience and the biological relevance of the data and any justification for acceptance of the data will be included in the report. - Statistics:
- The frequency of binucleate cells with micronuclei was compared, where necessary, with the concurrent vehicle control value using the Chi-squared Test on observed numbers of cells with micronuclei. Other statistical analyses may be used if appropriate (Hoffman et al., 2003). A toxicologically significant response was recorded when the p value calculated from the statistical analysis of the frequency of binucleate cells with micronuclei was less than 0.05 and there was a dose-related increase in the frequency of binucleate cells with micronuclei which was reproducible.
Results and discussion
Test results
- Key result
- Species / strain:
- lymphocytes: human
- Metabolic activation:
- with and without
- Genotoxicity:
- negative
- Cytotoxicity / choice of top concentrations:
- cytotoxicity
- Vehicle controls validity:
- valid
- Untreated negative controls validity:
- not applicable
- Positive controls validity:
- valid
- Additional information on results:
- TEST-SPECIFIC CONFOUNDING FACTORS
- Effects of pH and osmolality: There was no significant change in pH when the test item was dosed into media and the osmolality did not increase by more than 50 mOsm (Scott et al., 1991).
PRELIMINARY TOXICITY TEST:
- The dose range for the Preliminary Toxicity Test was 8.91 to 2280 µg/mL. The maximum dose was the 10 mM concentration.
- A precipitate of the test item was observed in the parallel blood-free cultures at the end of the exposure at and above 142.5 µg/mL in the exposure groups in the absence of S9-mix and at and above 285 µg/mL in the exposure group in the presence of S9-mix.
- Hemolysis was observed following exposure to the test item at and above 8.91 µg/mL in the 4-hour exposure group in the absence of S9-mix and at and above 35.63 µg/mL in both the presence of S9-mix and the 24-hour continuous exposure groups. Hemolysis is an indication of a cytotoxic effect to the erythrocytes and not indicative of any genotoxic response to the lymphocytes.
- Microscopic assessment of the slides prepared from the exposed cultures showed that binucleate cells were present at up to 35.63 µg/mL in the 4-hour exposure in the absence of S9-mix and at and above 71.25 µg/mL in both in the presence of S9-mix and the 24-hour exposure groups. The test item induced evidence of toxicity in all of the exposure groups.
- The selection of the maximum dose level for the Main Experiment was based on toxicity in the exposure groups in the absence of S9-mix and the lowest precipitating dose level for the exposure group in the presence of S9.
COMPARISON WITH HISTORICAL CONTROL DATA:
- The concurrent negative control was within the laboratory historical control data range.
ADDITIONAL INFORMATION ON CYTOTOXICITY:
Main experiments:
- The qualitative assessment of the slides determined that the toxicity was similar to that observed in the Preliminary Toxicity Test, particularly in the absence of S9-mix and that there were binucleate cells suitable for scoring at the maximum dose level of test item in all three exposure groups.
- A precipitate of test item was noted at 64 µg/mL in the 4-hour exposure group in the absence of S9-mix and at 96 µg/mL in the presence of S9-mix. No precipitate was observed in the 24-hour exposure group. Hemolysis was observed at all dose levels tested in all three exposure groups.
- The CBPI data for the 4 and 24-hour exposure groups confirm the qualitative observations in that a dose-related inhibition of CBPI was observed in the exposure groups in the absence of S9-mix. In the 4-hour exposure group in the absence of S9-mix, 27 and 55% cytostasis was achieved at 32 and 64 µg/mL, respectively whereas 41 and 55% cytostasis was observed at 56 and 64 µg/mL in the 24-hour exposure group. This indicated that the optimum level of toxicity was achieved in both exposure groups. In the presence of S9-mix, the level of cytostasis achieved at the maximum dose level was 26%, however a precipitate of the test item was observed at this dose level (96 µg/mL). The toxicity test had indicated that optimum toxicity may have been expected to have been achieved at between 56 and 80 µg/mL. Also, the level at which precipitate was observed in the 4-hour exposure groups was lower than that indicated by the toxicity test. Such inter-experimental minor differences are common in in vitro studies and do affect the validity of the results.
Therefore, the maximum dose level selected for analysis of binucleate cells was the maximum dose level in each exposure group and was limited by toxicity in the absence of S9-mix and by precipitate in the presence of S9-mix.
Any other information on results incl. tables
Table 7.6.1/1: pH and osmolality
Dose Concentration (µg/mL) |
0 |
8.92 |
17.84 |
35.67 |
71.34 |
142.69 |
285.38 |
570.75 |
1141.5 |
2283 |
pH |
7.49 |
7.45 |
7.43 |
7.44 |
7.46 |
7.46 |
7.46 |
7.45 |
7.45 |
7.45 |
Osmolality mOsm |
424 |
425 |
- |
423 |
425 |
420 |
- |
412 |
398 |
377 |
- = Not performed for this dose concentration
Table 7.6.1/2: CBPI and Micronucleus Data
Dose Level (μg/mL) |
Replicate |
Nucleate cells /500 cells |
CBPI |
% Control CBPI |
% Cytostasis |
Micronuclei (MN) per 1000 Binucleate cells |
%Cells with MN |
Mean % Cells with MN |
||||
Mono |
Bi |
Multi |
1 MN |
2 MN |
>2 MN |
|||||||
4 h Exposure Without Metabolic Activation (S9) |
||||||||||||
0 |
A |
231 |
212 |
57 |
1.65 |
100 |
0 |
8 |
0 |
0 |
0.80 |
0.70 |
B |
255 |
200 |
45 |
1.58 |
6 |
0 |
0 |
0.60 |
||||
24 |
A |
229 |
240 |
31 |
1.60 |
97 |
3 |
3 |
0 |
0 |
0.30 |
0.30 |
B |
247 |
205 |
48 |
1.60 |
3 |
0 |
0 |
0.30 |
||||
28 |
A |
290 |
176 |
34 |
1.49 |
81 |
19 |
3 |
0 |
1 |
0.40 |
0.40 |
B |
285 |
182 |
33 |
1.50 |
3 |
1 |
0 |
0.40 |
||||
32 |
A |
307 |
175 |
18 |
1.42 |
73 |
27 |
6 |
0 |
0 |
0.60 |
0.65 |
B |
283 |
195 |
22 |
1.48 |
6 |
1 |
0 |
0.70 |
||||
64 |
A |
354 |
135 |
11 |
1.31 |
45 |
55 |
4 |
0 |
0 |
0.40 |
0.25 |
B |
385 |
107 |
8 |
1.25 |
1 |
0 |
0 |
0.10 |
||||
MMC 0.2 |
A |
312 |
180 |
8 |
1.39 |
55 |
45 |
59 |
5 |
1 |
6.50 |
7.45*** |
B |
358 |
140 |
2 |
1.29 |
74 |
10 |
0 |
8.40 |
||||
4 h Exposure With Metabolic Activation (S9) |
||||||||||||
0 |
A |
190 |
253 |
57 |
1.73 |
100 |
0 |
1 |
0 |
0 |
0.10 |
0.30 |
B |
217 |
234 |
49 |
1.66 |
4 |
0 |
1 |
0.50 |
||||
56 |
A |
216 |
246 |
38 |
1.64 |
90 |
10 |
2 |
0 |
0 |
0.20 |
0.40 |
B |
223 |
243 |
34 |
1.62 |
6 |
0 |
0 |
0.60 |
||||
64 |
A |
194 |
260 |
46 |
1.70 |
87 |
13 |
3 |
0 |
0 |
0.30 |
0.45 |
B |
271 |
199 |
30 |
1.52 |
6 |
0 |
0 |
0.60 |
||||
80 |
A |
217 |
253 |
30 |
1.63 |
89 |
11 |
5 |
0 |
0 |
0.50 |
0.85 |
B |
230 |
237 |
33 |
1.61 |
12 |
0 |
0 |
1.20 |
||||
96 |
A |
278 |
197 |
25 |
1.49 |
74 |
26 |
1 |
0 |
0 |
0.10 |
0.30 |
B |
259 |
212 |
29 |
1.54 |
5 |
0 |
0 |
0.50 |
||||
CP 5 |
A |
322 |
167 |
11 |
1.38 |
44 |
56 |
30 |
2 |
0 |
3.20 |
5.30*** |
B |
378 |
122 |
0 |
1.24 |
67 |
6 |
1 |
7.40 |
||||
24 h Exposure Without Metabolic Activation (S9) |
||||||||||||
0 |
A |
92 |
352 |
56 |
1.93 |
100 |
0 |
4 |
0 |
0 |
0.40 |
0.45 |
B |
74 |
353 |
73 |
2.00 |
5 |
0 |
0 |
0.50 |
||||
32 |
A |
103 |
347 |
50 |
1.89 |
89 |
11 |
3 |
0 |
0 |
0.30 |
0.80 |
B |
121 |
343 |
36 |
1.83 |
1 |
12 |
0 |
1.30 |
||||
40 |
A |
156 |
312 |
32 |
1.75 |
80 |
20 |
3 |
0 |
0 |
0.30 |
0.35 |
B |
128 |
338 |
34 |
1.81 |
4 |
0 |
0 |
0.40 |
||||
56 |
A |
209 |
280 |
11 |
1.60 |
59 |
41 |
2 |
4 |
0 |
0.60 |
0.65 |
B |
242 |
247 |
11 |
1.54 |
5 |
2 |
0 |
0.70 |
||||
64 |
A |
324 |
173 |
3 |
1.36 |
45 |
55 |
7 |
0 |
0 |
0.70 |
0.50 |
B |
249 |
244 |
7 |
1.52 |
2 |
1 |
0 |
0.30 |
||||
DC 0.075 |
A |
228 |
233 |
39 |
1.62 |
57 |
43 |
44 |
8 |
1 |
5.30 |
4.50*** |
B |
289 |
181 |
30 |
1.48 |
27 |
10 |
0 |
3.70 |
MMC = Mitomycin C; CP = Cyclophosphamide; DC = Demecolcine; *** = P<0.001
Applicant's summary and conclusion
- Conclusions:
- negative with metabolic activation
negative without metabolic activation
Under the test conditions, test item was considered to be non-clastogenic and non-aneugenic to human lymphocytes in vitro. - Executive summary:
In an in vitro micronucleus test performed according to OECD Guideline 487 and in compliance with GLP, cultured peripheral human lymphocytes were exposed to test item in the presence and absence of a metabolic activation system. Three exposure conditions in a single experiment were used for the study using a 4‑hour exposure in the presence and absence of a standard metabolizing system (S9 at a 2% final concentration) and a 24-hour exposure in the absence of metabolic activation. At the end of the exposure period, the cell cultures were washed and then incubated for a further 24 hours in the presence of Cytochalasin B.
The dose levels used in the Main Experiment were selected using data from the preliminary toxicity test where the results indicated that the maximum concentration should be limited by the toxicity of the test item in the absence of S9-mix and limited by precipitate in the presence of S9-mix. The dose levels selected for the Main Test were as follows:
4-hour without S9: 0, 4, 8, 16, 24, 28, 32 and 64 μg/mL
4-hour with S9 (2%): 0, 8, 16, 32, 56, 64, 80 and 96 μg/mL
24-hour without S9: 0, 8, 16, 24, 32, 40, 56 and 64 μg/mL
All vehicle (dimethyl sulphoxide) controls had frequencies of cells with micronuclei within the range expected for normal human lymphocytes. The positive control items induced statistically significant increases in the frequency of cells with micronuclei. Thus, the sensitivity of the assay and the efficacy of the S9-mix were validated.
The test item was toxic to human lymphocytes but did not induce any statistically significant increases in the frequency of cells with micronuclei, using a dose range that included a dose level that induced approximately 50% reduction in CBPI in the absence of S9-mix and was the lowest precipitating dose level in the presence of S9-mix.
Under the test conditions, test item was considered to be non-clastogenic and non-aneugenic to human lymphocytes in vitro.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.